# NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

> **NCT05881525** · PHASE1 · RECRUITING · sponsor: **TCRCure Biopharma Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** TC-N201 cells
- **DRUG:** IL-2
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05881525
- **Lead sponsor:** TCRCure Biopharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05881525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05881525, "NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05881525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*